NXGL nexgel.com: Company Value to Revenue

Official company branding of NEXGEL (NXGL)

Is it worth investing in NEXGEL, Inc. (NXGL), whose revenues rely on the regular sale of consumables to clinics? The EV/Revenue ratio provides the answer: the metric's value is 1613.32. The trend of this indicator reflects market expectations, where growth signals development and sharp peaks suggest a correction. The business remains crisis-resilient due to stable hospital demand and the implementation of innovative polymers for wound healing.

nexgel.com (NXGL): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

NXGL (NEXGEL Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
Initial company analysis:NEXGEL, Inc., NXGL
Manufactured products of NEXGEL, Inc

To identify fundamental sector leaders, it is critical to evaluate enterprise value including net debt relative to revenue, which eliminates the impact of debt load on investment attractiveness. The current value of 1613.32 reflects the market value of NEXGEL, Inc. (NXGL) innovations in transdermal drug delivery, allowing the enterprise value-to-revenue ratio to determine the resilience of high-tech R&D leadership against market volatility.

Competitor analysis for NEXGEL, Inc.

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|STSS - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio InfuSystem Holdings, Inc.|Enterprise Value-to-Revenue Multiple Utah Medical Products UTMD|EV/Sales Multiple KRMD|Total Company Value-to-Revenue Ratio Nyxoah, S.A.|Microbot Medical Inc - Company Value to Revenue|Total Company Value-to-Revenue Ratio Pro-Dex Inc. (PDEX)|Zentek - EV/Sales Multiple|Elutia (ELUT) - Company Value to Revenue|Milestone Scientific Inc (MLSS) - Enterprise Value-to-Revenue Ratio|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple